nodes	percent_of_prediction	percent_of_DWPC	metapath
Triamterene—Irreversible renal failure—Mitomycin—urinary bladder cancer	0.105	0.224	CcSEcCtD
Triamterene—Irreversible renal failure—Gemcitabine—urinary bladder cancer	0.0444	0.0949	CcSEcCtD
Triamterene—Irreversible renal failure—Cisplatin—urinary bladder cancer	0.0414	0.0885	CcSEcCtD
Triamterene—Renal failure chronic—Mitomycin—urinary bladder cancer	0.0368	0.0785	CcSEcCtD
Triamterene—SCNN1G—prostate gland—urinary bladder cancer	0.0273	0.0698	CbGeAlD
Triamterene—SCNN1D—prostate gland—urinary bladder cancer	0.0273	0.0698	CbGeAlD
Triamterene—SCNN1G—seminal vesicle—urinary bladder cancer	0.0231	0.059	CbGeAlD
Triamterene—SCNN1B—prostate gland—urinary bladder cancer	0.023	0.059	CbGeAlD
Triamterene—SCNN1A—prostate gland—urinary bladder cancer	0.0213	0.0545	CbGeAlD
Triamterene—SCNN1D—epithelium—urinary bladder cancer	0.02	0.0513	CbGeAlD
Triamterene—SCNN1G—renal system—urinary bladder cancer	0.0186	0.0476	CbGeAlD
Triamterene—SCNN1G—urethra—urinary bladder cancer	0.0183	0.0467	CbGeAlD
Triamterene—SCNN1B—epithelium—urinary bladder cancer	0.0169	0.0433	CbGeAlD
Triamterene—SCNN1B—renal system—urinary bladder cancer	0.0157	0.0402	CbGeAlD
Triamterene—SCNN1A—epithelium—urinary bladder cancer	0.0156	0.04	CbGeAlD
Triamterene—Renal failure chronic—Gemcitabine—urinary bladder cancer	0.0156	0.0332	CcSEcCtD
Triamterene—SCNN1B—urethra—urinary bladder cancer	0.0154	0.0395	CbGeAlD
Triamterene—SCNN1G—female reproductive system—urinary bladder cancer	0.0149	0.0381	CbGeAlD
Triamterene—SCNN1D—female reproductive system—urinary bladder cancer	0.0149	0.0381	CbGeAlD
Triamterene—SCNN1A—renal system—urinary bladder cancer	0.0145	0.0371	CbGeAlD
Triamterene—Renal failure chronic—Cisplatin—urinary bladder cancer	0.0145	0.031	CcSEcCtD
Triamterene—SCNN1A—urethra—urinary bladder cancer	0.0143	0.0365	CbGeAlD
Triamterene—CYP1A2—urine—urinary bladder cancer	0.0142	0.0365	CbGeAlD
Triamterene—Blood urea increased—Valrubicin—urinary bladder cancer	0.0136	0.029	CcSEcCtD
Triamterene—SCNN1G—vagina—urinary bladder cancer	0.0135	0.0345	CbGeAlD
Triamterene—SCNN1B—female reproductive system—urinary bladder cancer	0.0126	0.0322	CbGeAlD
Triamterene—SCNN1A—female reproductive system—urinary bladder cancer	0.0116	0.0297	CbGeAlD
Triamterene—SCNN1B—vagina—urinary bladder cancer	0.0114	0.0291	CbGeAlD
Triamterene—Anaemia megaloblastic—Methotrexate—urinary bladder cancer	0.0091	0.0194	CcSEcCtD
Triamterene—SCNN1D—lymph node—urinary bladder cancer	0.00871	0.0223	CbGeAlD
Triamterene—SCNN1D—Stimuli-sensing channels—TRPV1—urinary bladder cancer	0.00867	0.0615	CbGpPWpGaD
Triamterene—SCNN1G—Stimuli-sensing channels—TRPV1—urinary bladder cancer	0.00867	0.0615	CbGpPWpGaD
Triamterene—SCNN1A—Stimuli-sensing channels—TRPV1—urinary bladder cancer	0.00867	0.0615	CbGpPWpGaD
Triamterene—SCNN1B—Stimuli-sensing channels—TRPV1—urinary bladder cancer	0.00867	0.0615	CbGpPWpGaD
Triamterene—SCNN1B—lymph node—urinary bladder cancer	0.00736	0.0188	CbGeAlD
Triamterene—SCNN1A—lymph node—urinary bladder cancer	0.0068	0.0174	CbGeAlD
Triamterene—SCNN1G—Ion channel transport—TRPV1—urinary bladder cancer	0.00565	0.0401	CbGpPWpGaD
Triamterene—SCNN1B—Ion channel transport—TRPV1—urinary bladder cancer	0.00565	0.0401	CbGpPWpGaD
Triamterene—SCNN1D—Ion channel transport—TRPV1—urinary bladder cancer	0.00565	0.0401	CbGpPWpGaD
Triamterene—SCNN1A—Ion channel transport—TRPV1—urinary bladder cancer	0.00565	0.0401	CbGpPWpGaD
Triamterene—Blood urea increased—Thiotepa—urinary bladder cancer	0.0047	0.01	CcSEcCtD
Triamterene—CYP1A2—Arylamine metabolism—NAT2—urinary bladder cancer	0.00457	0.0324	CbGpPWpGaD
Triamterene—Azotaemia—Methotrexate—urinary bladder cancer	0.00402	0.00859	CcSEcCtD
Triamterene—Blood urea increased—Gemcitabine—urinary bladder cancer	0.00396	0.00845	CcSEcCtD
Triamterene—Hyperkalaemia—Cisplatin—urinary bladder cancer	0.00384	0.00819	CcSEcCtD
Triamterene—Asthenia—Valrubicin—urinary bladder cancer	0.00368	0.00786	CcSEcCtD
Triamterene—Diarrhoea—Valrubicin—urinary bladder cancer	0.00351	0.00749	CcSEcCtD
Triamterene—CYP1A2—renal system—urinary bladder cancer	0.00348	0.00892	CbGeAlD
Triamterene—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.00346	0.00739	CcSEcCtD
Triamterene—Photosensitivity—Fluorouracil—urinary bladder cancer	0.00341	0.00727	CcSEcCtD
Triamterene—Dizziness—Valrubicin—urinary bladder cancer	0.00339	0.00724	CcSEcCtD
Triamterene—SCNN1A—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00334	0.0237	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00334	0.0237	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00334	0.0237	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00334	0.0237	CbGpPWpGaD
Triamterene—Vomiting—Valrubicin—urinary bladder cancer	0.00326	0.00696	CcSEcCtD
Triamterene—Rash—Valrubicin—urinary bladder cancer	0.00323	0.00691	CcSEcCtD
Triamterene—Dermatitis—Valrubicin—urinary bladder cancer	0.00323	0.0069	CcSEcCtD
Triamterene—Headache—Valrubicin—urinary bladder cancer	0.00321	0.00686	CcSEcCtD
Triamterene—CYP1A2—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00317	0.0225	CbGpPWpGaD
Triamterene—Renal failure acute—Cisplatin—urinary bladder cancer	0.00307	0.00656	CcSEcCtD
Triamterene—Nausea—Valrubicin—urinary bladder cancer	0.00305	0.00651	CcSEcCtD
Triamterene—Fatigue—Mitomycin—urinary bladder cancer	0.00305	0.00651	CcSEcCtD
Triamterene—CYP1A2—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.0028	0.0199	CbGpPWpGaD
Triamterene—Hypokalaemia—Gemcitabine—urinary bladder cancer	0.00277	0.00591	CcSEcCtD
Triamterene—Jaundice—Thiotepa—urinary bladder cancer	0.00272	0.0058	CcSEcCtD
Triamterene—Hypokalaemia—Cisplatin—urinary bladder cancer	0.00258	0.00551	CcSEcCtD
Triamterene—Asthenia—Mitomycin—urinary bladder cancer	0.00254	0.00541	CcSEcCtD
Triamterene—Diarrhoea—Mitomycin—urinary bladder cancer	0.00242	0.00516	CcSEcCtD
Triamterene—SCNN1G—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.00241	0.0171	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.00241	0.0171	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.00241	0.0171	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.00241	0.0171	CbGpPWpGaD
Triamterene—Photosensitivity reaction—Fluorouracil—urinary bladder cancer	0.00236	0.00504	CcSEcCtD
Triamterene—Dizziness—Mitomycin—urinary bladder cancer	0.00234	0.00499	CcSEcCtD
Triamterene—CYP1A2—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00227	0.0161	CbGpPWpGaD
Triamterene—Vomiting—Mitomycin—urinary bladder cancer	0.00225	0.0048	CcSEcCtD
Triamterene—Rash—Mitomycin—urinary bladder cancer	0.00223	0.00476	CcSEcCtD
Triamterene—Dermatitis—Mitomycin—urinary bladder cancer	0.00223	0.00475	CcSEcCtD
Triamterene—Headache—Mitomycin—urinary bladder cancer	0.00221	0.00473	CcSEcCtD
Triamterene—Nausea—Mitomycin—urinary bladder cancer	0.0021	0.00448	CcSEcCtD
Triamterene—CYP1A2—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00199	0.0141	CbGpPWpGaD
Triamterene—Hyperkalaemia—Epirubicin—urinary bladder cancer	0.00197	0.00421	CcSEcCtD
Triamterene—SCNN1A—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.00197	0.014	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.00197	0.014	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.00197	0.014	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.00197	0.014	CbGpPWpGaD
Triamterene—Jaundice—Etoposide—urinary bladder cancer	0.00195	0.00417	CcSEcCtD
Triamterene—Blood urea increased—Epirubicin—urinary bladder cancer	0.00189	0.00404	CcSEcCtD
Triamterene—Hyperkalaemia—Doxorubicin—urinary bladder cancer	0.00182	0.00389	CcSEcCtD
Triamterene—Photosensitivity—Methotrexate—urinary bladder cancer	0.00177	0.00378	CcSEcCtD
Triamterene—Blood urea increased—Doxorubicin—urinary bladder cancer	0.00175	0.00374	CcSEcCtD
Triamterene—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.00174	0.00372	CcSEcCtD
Triamterene—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00171	0.0122	CbGpPWpGaD
Triamterene—Renal failure acute—Methotrexate—urinary bladder cancer	0.00169	0.0036	CcSEcCtD
Triamterene—Photosensitivity—Epirubicin—urinary bladder cancer	0.00166	0.00354	CcSEcCtD
Triamterene—Renal failure acute—Epirubicin—urinary bladder cancer	0.00158	0.00337	CcSEcCtD
Triamterene—Photosensitivity—Doxorubicin—urinary bladder cancer	0.00153	0.00328	CcSEcCtD
Triamterene—Fatigue—Thiotepa—urinary bladder cancer	0.00153	0.00327	CcSEcCtD
Triamterene—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00149	0.00319	CcSEcCtD
Triamterene—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00147	0.00314	CcSEcCtD
Triamterene—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00146	0.00313	CcSEcCtD
Triamterene—Renal failure acute—Doxorubicin—urinary bladder cancer	0.00146	0.00312	CcSEcCtD
Triamterene—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00144	0.00307	CcSEcCtD
Triamterene—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00139	0.00298	CcSEcCtD
Triamterene—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.00136	0.00291	CcSEcCtD
Triamterene—SCNN1B—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.00133	0.00943	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.00133	0.00943	CbGpPWpGaD
Triamterene—SCNN1D—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.00133	0.00943	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.00133	0.00943	CbGpPWpGaD
Triamterene—Hypokalaemia—Epirubicin—urinary bladder cancer	0.00132	0.00283	CcSEcCtD
Triamterene—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00131	0.0028	CcSEcCtD
Triamterene—Fatigue—Gemcitabine—urinary bladder cancer	0.00129	0.00275	CcSEcCtD
Triamterene—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00128	0.00273	CcSEcCtD
Triamterene—Asthenia—Thiotepa—urinary bladder cancer	0.00128	0.00272	CcSEcCtD
Triamterene—CYP1A2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00126	0.00893	CbGpPWpGaD
Triamterene—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00125	0.00267	CcSEcCtD
Triamterene—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.00123	0.00262	CcSEcCtD
Triamterene—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.00123	0.00262	CcSEcCtD
Triamterene—CYP1A2—Estrogen metabolism—NQO1—urinary bladder cancer	0.00122	0.00867	CbGpPWpGaD
Triamterene—Diarrhoea—Thiotepa—urinary bladder cancer	0.00122	0.0026	CcSEcCtD
Triamterene—Dizziness—Thiotepa—urinary bladder cancer	0.00118	0.00251	CcSEcCtD
Triamterene—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.00115	0.00245	CcSEcCtD
Triamterene—Vomiting—Thiotepa—urinary bladder cancer	0.00113	0.00241	CcSEcCtD
Triamterene—Rash—Thiotepa—urinary bladder cancer	0.00112	0.00239	CcSEcCtD
Triamterene—Dermatitis—Thiotepa—urinary bladder cancer	0.00112	0.00239	CcSEcCtD
Triamterene—Headache—Thiotepa—urinary bladder cancer	0.00111	0.00238	CcSEcCtD
Triamterene—Fatigue—Etoposide—urinary bladder cancer	0.0011	0.00235	CcSEcCtD
Triamterene—Jaundice—Epirubicin—urinary bladder cancer	0.00109	0.00234	CcSEcCtD
Triamterene—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00109	0.00772	CbGpPWpGaD
Triamterene—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00108	0.00231	CcSEcCtD
Triamterene—CYP1A2—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00107	0.00762	CbGpPWpGaD
Triamterene—Asthenia—Gemcitabine—urinary bladder cancer	0.00107	0.00229	CcSEcCtD
Triamterene—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.00106	0.00227	CcSEcCtD
Triamterene—Nausea—Thiotepa—urinary bladder cancer	0.00106	0.00225	CcSEcCtD
Triamterene—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00103	0.00219	CcSEcCtD
Triamterene—CYP1A2—Phase II conjugation—GSTZ1—urinary bladder cancer	0.00103	0.00728	CbGpPWpGaD
Triamterene—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00102	0.00218	CcSEcCtD
Triamterene—Jaundice—Doxorubicin—urinary bladder cancer	0.00101	0.00216	CcSEcCtD
Triamterene—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00101	0.00215	CcSEcCtD
Triamterene—Asthenia—Cisplatin—urinary bladder cancer	0.001	0.00213	CcSEcCtD
Triamterene—CYP1A2—Phase II conjugation—GSTO2—urinary bladder cancer	0.000973	0.0069	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—NAT1—urinary bladder cancer	0.000973	0.0069	CbGpPWpGaD
Triamterene—Dizziness—Fluorouracil—urinary bladder cancer	0.000972	0.00208	CcSEcCtD
Triamterene—CYP1A2—Estrogen Receptor Pathway—ESR1—urinary bladder cancer	0.000955	0.00677	CbGpPWpGaD
Triamterene—Diarrhoea—Cisplatin—urinary bladder cancer	0.000953	0.00204	CcSEcCtD
Triamterene—Vomiting—Gemcitabine—urinary bladder cancer	0.00095	0.00203	CcSEcCtD
Triamterene—Rash—Gemcitabine—urinary bladder cancer	0.000943	0.00201	CcSEcCtD
Triamterene—Dermatitis—Gemcitabine—urinary bladder cancer	0.000942	0.00201	CcSEcCtD
Triamterene—Hypersensitivity—Etoposide—urinary bladder cancer	0.00094	0.00201	CcSEcCtD
Triamterene—CYP1A2—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000937	0.00665	CbGpPWpGaD
Triamterene—Headache—Gemcitabine—urinary bladder cancer	0.000937	0.002	CcSEcCtD
Triamterene—Vomiting—Fluorouracil—urinary bladder cancer	0.000935	0.002	CcSEcCtD
Triamterene—Rash—Fluorouracil—urinary bladder cancer	0.000927	0.00198	CcSEcCtD
Triamterene—Dermatitis—Fluorouracil—urinary bladder cancer	0.000926	0.00198	CcSEcCtD
Triamterene—Headache—Fluorouracil—urinary bladder cancer	0.000921	0.00197	CcSEcCtD
Triamterene—Asthenia—Etoposide—urinary bladder cancer	0.000916	0.00196	CcSEcCtD
Triamterene—CYP1A2—Phase II conjugation—UGT2B7—urinary bladder cancer	0.00089	0.00631	CbGpPWpGaD
Triamterene—Nausea—Gemcitabine—urinary bladder cancer	0.000888	0.0019	CcSEcCtD
Triamterene—Vomiting—Cisplatin—urinary bladder cancer	0.000886	0.00189	CcSEcCtD
Triamterene—CYP1A2—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000882	0.00626	CbGpPWpGaD
Triamterene—Rash—Cisplatin—urinary bladder cancer	0.000879	0.00188	CcSEcCtD
Triamterene—Dermatitis—Cisplatin—urinary bladder cancer	0.000878	0.00187	CcSEcCtD
Triamterene—Diarrhoea—Etoposide—urinary bladder cancer	0.000873	0.00186	CcSEcCtD
Triamterene—Nausea—Fluorouracil—urinary bladder cancer	0.000873	0.00186	CcSEcCtD
Triamterene—Dizziness—Etoposide—urinary bladder cancer	0.000844	0.0018	CcSEcCtD
Triamterene—Nausea—Cisplatin—urinary bladder cancer	0.000828	0.00177	CcSEcCtD
Triamterene—Vomiting—Etoposide—urinary bladder cancer	0.000812	0.00173	CcSEcCtD
Triamterene—Rash—Etoposide—urinary bladder cancer	0.000805	0.00172	CcSEcCtD
Triamterene—Dermatitis—Etoposide—urinary bladder cancer	0.000804	0.00172	CcSEcCtD
Triamterene—Headache—Etoposide—urinary bladder cancer	0.0008	0.00171	CcSEcCtD
Triamterene—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000765	0.00163	CcSEcCtD
Triamterene—Nausea—Etoposide—urinary bladder cancer	0.000758	0.00162	CcSEcCtD
Triamterene—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000749	0.0016	CcSEcCtD
Triamterene—Dry mouth—Epirubicin—urinary bladder cancer	0.00073	0.00156	CcSEcCtD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000716	0.00508	CbGpPWpGaD
Triamterene—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000716	0.00153	CcSEcCtD
Triamterene—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000701	0.0015	CcSEcCtD
Triamterene—Dry mouth—Doxorubicin—urinary bladder cancer	0.000675	0.00144	CcSEcCtD
Triamterene—CYP1A2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.00067	0.00475	CbGpPWpGaD
Triamterene—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000662	0.00141	CcSEcCtD
Triamterene—Fatigue—Methotrexate—urinary bladder cancer	0.000659	0.00141	CcSEcCtD
Triamterene—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000648	0.00138	CcSEcCtD
Triamterene—SCNN1D—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000622	0.00441	CbGpPWpGaD
Triamterene—SCNN1B—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000622	0.00441	CbGpPWpGaD
Triamterene—SCNN1G—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000622	0.00441	CbGpPWpGaD
Triamterene—SCNN1A—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000622	0.00441	CbGpPWpGaD
Triamterene—Fatigue—Epirubicin—urinary bladder cancer	0.000617	0.00132	CcSEcCtD
Triamterene—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.0006	0.00426	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000592	0.0042	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.000577	0.00409	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000577	0.00409	CbGpPWpGaD
Triamterene—Fatigue—Doxorubicin—urinary bladder cancer	0.000571	0.00122	CcSEcCtD
Triamterene—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000569	0.00404	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000569	0.00404	CbGpPWpGaD
Triamterene—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000563	0.0012	CcSEcCtD
Triamterene—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000561	0.00398	CbGpPWpGaD
Triamterene—Asthenia—Methotrexate—urinary bladder cancer	0.000549	0.00117	CcSEcCtD
Triamterene—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.000533	0.00378	CbGpPWpGaD
Triamterene—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000527	0.00113	CcSEcCtD
Triamterene—Diarrhoea—Methotrexate—urinary bladder cancer	0.000523	0.00112	CcSEcCtD
Triamterene—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.00052	0.00369	CbGpPWpGaD
Triamterene—Asthenia—Epirubicin—urinary bladder cancer	0.000513	0.0011	CcSEcCtD
Triamterene—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000513	0.00364	CbGpPWpGaD
Triamterene—Dizziness—Methotrexate—urinary bladder cancer	0.000506	0.00108	CcSEcCtD
Triamterene—Diarrhoea—Epirubicin—urinary bladder cancer	0.00049	0.00105	CcSEcCtD
Triamterene—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000488	0.00104	CcSEcCtD
Triamterene—Vomiting—Methotrexate—urinary bladder cancer	0.000486	0.00104	CcSEcCtD
Triamterene—Rash—Methotrexate—urinary bladder cancer	0.000482	0.00103	CcSEcCtD
Triamterene—Dermatitis—Methotrexate—urinary bladder cancer	0.000482	0.00103	CcSEcCtD
Triamterene—Headache—Methotrexate—urinary bladder cancer	0.000479	0.00102	CcSEcCtD
Triamterene—Asthenia—Doxorubicin—urinary bladder cancer	0.000475	0.00101	CcSEcCtD
Triamterene—Dizziness—Epirubicin—urinary bladder cancer	0.000473	0.00101	CcSEcCtD
Triamterene—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.000469	0.00332	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000462	0.00328	CbGpPWpGaD
Triamterene—Vomiting—Epirubicin—urinary bladder cancer	0.000455	0.000971	CcSEcCtD
Triamterene—Nausea—Methotrexate—urinary bladder cancer	0.000454	0.00097	CcSEcCtD
Triamterene—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000453	0.000967	CcSEcCtD
Triamterene—Rash—Epirubicin—urinary bladder cancer	0.000451	0.000963	CcSEcCtD
Triamterene—Dermatitis—Epirubicin—urinary bladder cancer	0.000451	0.000962	CcSEcCtD
Triamterene—Headache—Epirubicin—urinary bladder cancer	0.000448	0.000957	CcSEcCtD
Triamterene—Dizziness—Doxorubicin—urinary bladder cancer	0.000438	0.000935	CcSEcCtD
Triamterene—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	0.000426	0.00302	CbGpPWpGaD
Triamterene—Nausea—Epirubicin—urinary bladder cancer	0.000425	0.000908	CcSEcCtD
Triamterene—Vomiting—Doxorubicin—urinary bladder cancer	0.000421	0.000899	CcSEcCtD
Triamterene—Rash—Doxorubicin—urinary bladder cancer	0.000417	0.000891	CcSEcCtD
Triamterene—Dermatitis—Doxorubicin—urinary bladder cancer	0.000417	0.000891	CcSEcCtD
Triamterene—Headache—Doxorubicin—urinary bladder cancer	0.000415	0.000886	CcSEcCtD
Triamterene—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	0.000413	0.00293	CbGpPWpGaD
Triamterene—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000404	0.00286	CbGpPWpGaD
Triamterene—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000396	0.00281	CbGpPWpGaD
Triamterene—Nausea—Doxorubicin—urinary bladder cancer	0.000393	0.00084	CcSEcCtD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000347	0.00246	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.000312	0.00221	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000308	0.00218	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000303	0.00215	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000286	0.00203	CbGpPWpGaD
Triamterene—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000263	0.00187	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000249	0.00177	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000249	0.00177	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000242	0.00172	CbGpPWpGaD
Triamterene—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000233	0.00165	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000231	0.00164	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000218	0.00155	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000207	0.00147	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000207	0.00147	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000202	0.00143	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000202	0.00143	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000181	0.00128	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00018	0.00128	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000177	0.00125	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000177	0.00125	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000168	0.00119	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000168	0.00119	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000168	0.00119	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000167	0.00118	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000165	0.00117	CbGpPWpGaD
Triamterene—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	0.000154	0.00109	CbGpPWpGaD
Triamterene—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000152	0.00108	CbGpPWpGaD
Triamterene—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000142	0.00101	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	0.000103	0.000728	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	9.73e-05	0.00069	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—NAT1—urinary bladder cancer	9.73e-05	0.00069	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	9.57e-05	0.000679	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	8.9e-05	0.000631	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	8.01e-05	0.000568	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	7.57e-05	0.000537	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	7.38e-05	0.000523	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.91e-05	0.000419	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—TYMP—urinary bladder cancer	5.9e-05	0.000418	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.66e-05	0.000402	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—NAT2—urinary bladder cancer	5.33e-05	0.000378	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—RRM2—urinary bladder cancer	4.6e-05	0.000327	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	4.26e-05	0.000302	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—ENO2—urinary bladder cancer	4.26e-05	0.000302	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.24e-05	0.000301	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	4.13e-05	0.000293	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.07e-05	0.000289	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—NQO1—urinary bladder cancer	3.44e-05	0.000244	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.33e-05	0.000236	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.91e-05	0.000206	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.87e-05	0.000203	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.77e-05	0.000197	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.66e-05	0.000189	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.63e-05	0.000187	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.63e-05	0.000187	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—GPX1—urinary bladder cancer	2.52e-05	0.000179	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	2.48e-05	0.000176	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.33e-05	0.000165	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.89e-05	0.000134	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.81e-05	0.000129	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.48e-05	0.000105	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.29e-05	9.18e-05	CbGpPWpGaD
Triamterene—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.23e-05	8.76e-05	CbGpPWpGaD
